<DOC>
	<DOCNO>NCT01947556</DOCNO>
	<brief_summary>The purpose study compare pharmacokinetic pharmacodynamic profile rapid-acting insulin analogue aspart ( Novorapid® ) inject subcutaneously jet-injection insulin inject conventional pen management hyperglycemia subject diabetes</brief_summary>
	<brief_title>Insulin Jet-injection Hyperglycemia Diabetes</brief_title>
	<detailed_description>Recently , show healthy , non-diabetic volunteer patient type 1 ( T1DM ) insulin-treated type 2 diabetes ( T2DM ) 40-50 % fast absorption rapid-acting insulin analogue administer jet injection technology rather conventional insulin pen . The fast insulin action insulin administration jet injection may especially advantageous correction hyperglycemia . To investigate , open-label randomise control cross-over study perform 20 adult patient ( 18-75 year ) T1DM T2DM basal-bolus insulin treatment . The pharmacokinetic pharmacodynamic profile insulin aspart derive time-action profile insulin glucose , respectively , response insulin ( dose 1.5 time amount insulin need reduce blood glucose 6 mmol/l calculate insulin-sensitivity factor ) reach hyperglycemia ( 18-23 mmol/l ) . All patient investigate twice , one occasion jet-injector device use inject insulin , occasion insulin inject conventional insulin pen . The order occasion randomise . Both device operate patient sufficient training . Ease use evaluate .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Hyperglycemia</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>diabetes mellitus type 1 2 Age 1875 year BodyMass Index ≥25 kg/m2 ≤40 kg/m2 Stable glycaemic control HbA1c ≥48 ( 6.5 % ) ≤86 mmol/mol ( 10 % ) Insulin treatment accord basalbolus regimen , i.e . multiple daily injection least four time daily , subcutaneous insulin pump , least 12 month , use metformin allow Inability provide inform consent Insulin requirement &lt; 34 &gt; 200 unit per day Treatment systemic corticosteroid , immunosuppressive cytostatic drug Known allergy aspart insulin Use oral antidiabetic drug metformin Symptomatic diabetic neuropathy History major cardiovascular disease event ( myocardial infarction , stroke , symptomatic peripheral artery disease , coronary bypass surgery , percutaneous coronary peripheral artery angioplasty ) previous 6 month Pregnancy intention become pregnant Renal disease ( creatinine &gt; 150 μmol/l MDRDGFR &lt; 30 ml/min/1.73m2 ) Liver disease ( aspartate aminotransferase alanine aminotransferase level three time upper limit normal range ) Presence medical condition might interfere study protocol anemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>diabetes</keyword>
	<keyword>insulin administration</keyword>
	<keyword>hyperglycaemia</keyword>
	<keyword>insulin aspart</keyword>
</DOC>